Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma
By J. Weber, M. Mandalà, M. Del Vecchio, H. Gogas, A. Arance, L. Cowey, S. Dalle, M. Schenker, V. Chiarion-Sileni, I. Márquez-Rodas and 24 more. New England Journal of Medicine, 2017
1,939 citations recorded by the source corpus.
Subfields: Molecular Biology, Oncology
View Paper: https://www.semanticscholar.org/paper/b6437ee34ebc994afcd20cf0a3f1c3382d9dc845
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Molecular Biology
In Oncology
- D. Pardoll
- Janis Taube
- S. Topalian
- K. Flaherty
- Georgina V. Long
- Lieping Chen
- Antoni Ribas
- J. Wolchok
Citations in the corpus
- Melanoma Staging: Evidence-Based Changes in the American Joint Committee on Cancer Eighth Edition Cancer Staging Manual (2017, background): “Moreover, adjuvant therapy with new agents has shown impressive ability to improve clinical outcomes in patients with resected stage III melanoma.(22-24) It is against this background that the AJCC appointed a Melanoma Expert Panel to undertake the task of revising the cutaneous melanoma staging sys”
- Cutaneous melanoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†. (2019, neutral): “Additionally, results from CheckMate 238 suggest that nivolumab had benefits for stage IV no evidence of disease (NED) similar to those of stage III, making it a clear option for this patient population [56].”
- Neoadjuvant checkpoint blockade for cancer immunotherapy (2020, background): “In surgically resectable metastatic melanoma (stages IIIA to IV), randomized phase 3 clinical trials demonstrated the efficacy of adjuvant anti– PD-1 therapy, leading the FDA to approve nivolumab and pembrolizumab for this indication (8, 9).”